search icon
Join IDSAJOIN IDSA >> Go to MyIDSAGO TO MYIDSA >>
  • Print
  • ShareThis
  • Text Size
  •  

    2016 Board of Directors Candidates 

    The bios for the candidates for the 2016 Board of Directors elections are listed below for both IDSA and HIVMA.

     

    IDSA Board of Directors 2016 Candidates

  • IDSA Vice President - Kathryn M. Edwards, MD, FIDSA

    Education: Grinnell College, University of Iowa College of Pharmacy, University of Iowa College of Medicine, MD (1973); Pediatric Residency/Infectious Diseases Fellowship, Children's Memorial Hospital, Northwestern University (1973-78); Postdoctoral Fellow in Immunology, Presbyterian St. Luke's Hospital, Rush Medical School (1978-80).

    Current Appointments: Sarah H. Sell and Cornelius Vanderbilt Endowed Professor in Pediatrics, Director of Clinical Infectious Diseases and Interim Director of Antibiotic Stewardship, Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee.

    IDSA Participation: Fellowship Awards Committee (1998-2001); Nominations Committee (1998-2001); Program Committee (1998-2001); Member of IDSA Council (2002-2005); Secretary, IDSA Council (2011-2014); Publications Committee (2011-2014); Clinical Infectious Diseases Journal, Associate Editor (2016-).

    Research Interests: Dr. Edwards has spent much of her career evaluating the safety, immunogenicity and effectiveness of vaccines, facilitating their implementation, and assessing their impact with federal funding from the NIH and CDC. She has also had an active clinical practice for nearly four decades and has studied periodic fever syndromes, the etiology and burden of pneumonia in adults and children, and the management of complicated infections. She has mentored numerous young investigators who have gone on to productive careers in infectious diseases.

    Other: Member of the CDC Advisory Committee on Immunization Practices (1991-1995); Mentoring Award and Grant W. Liddle Award for Excellence in Research, Vanderbilt University (2001); Alexander Heard Distinguished Professor Award at Vanderbilt (2005); IDSA Mentor Award (2006); Election to the Institute of Medicine, National Academy of Science (2008); Member, Committee on Infectious Diseases, AAP (2010-2016); Member of Advisory Council, NIH, NIAID (2008-2011); Distinguished Physician Award, Pediatric Infectious Diseases Society (2011); Member of Board of Scientific Counselors, NIH, NIAID (2011-2014); Lifetime Contribution to Infectious Diseases Education, AAP  (2013); Maureen Andrew Mentoring Award, Society for Pediatric Research (2014); Charles Mérieux Vaccinology Award, NFID (2016); Chair of the FDA Vaccines and Related Biological Products Advisory Committee (2016-).

    Personal Statement: Current challenges to the study and practice of infectious diseases abound, from fewer young physicians entering the field to emerging pathogens, mounting antimicrobial resistance and an increasingly complex environment for delivery of care. I have seen IDSA emerge as a leader on many fronts and have been passionate about participating in the process.  My multifaceted career as a clinician, researcher, mentor and administrator has provided me with the expertise and experience to bring innovative leadership to IDSA. I am at a stage in my career where I have the flexibility to devote the significant time that this job deserves and demands.  I would be proud to serve as president of the IDSA Board to support its important missions, address these challenges and inspire the next generation of leaders.

    IDSA Vice President - Cynthia L. Sears, MD, FIDSA

    Education:  Pennsylvania State University, BS, 1975,; Thomas Jefferson School of Medicine, MD, 1977; The New York Hospital/Cornell Medical Center, Intern and Resident in Internal Medicine, 1977-1980, Assistant Chief Resident, 1980; The New York Hospital/Cornell Medical Center, Henry J. Kaiser Foundation Fellow in General Internal Medicine, 1980-1981; Memorial Hospital/Sloan Kettering Institute, Fellow in Infectious Diseases, 1981-1982; University of Virginia Medical Center, Fellow in Infectious Diseases, 1982-1985.

    Current Appointments:  Professor of Medicine and Molecular Microbiology and Immunology, Johns Hopkins University School of Medicine and Bloomberg School of Public Health; Attending Physician, Johns Hopkins Hospital.

    IDSA Participation:  Program and Abstract Selection Committee, 1995-1996; Fellowship and Young Investigator Grants Award Committee, 1996-1998; IDSA Strategic Planning Retreat, 1997; Nominating Committee, 1997-1998; Training Director's Committee, 2000-2004; Annual Meeting Program Committee, 2000-2004 (Vice Chair, 2002; Chair, 2003, Past Chair, 2004); Board of Directors, 2004-2007; Vice Chair, IDSA Education and Research Foundation, 2005-2007; Publications Committee, 2004-2007; Member, Communications Committee, 2007-2009; Co-convener, Vincent Andriole ID Board Review Course, 2008-2011; Member, Special Task Force on Publishing, 2008-2009; IDSA Treasurer, 2009-2015; Member, Clinical Infectious Diseases Editor Search, 2015; Member, IDSA Task Force for Executive Director, 2015-2016; Chair, Task Force on Guideline Development, 2016.

    Research Interests:  Bacterial pathogenesis; contribution of specific bacteria and the microbiome to colon cancer development.

    Other:  Director, Infectious Diseases Fellowship Program, Johns Hopkins University School of Medicine, 1992-2006; Elected, American Society for Clinical Investigation, 1996; Permanent Member, Bacteriology and Mycology Study Section, 1998-2002; Chair, Task Force on the Status of Academic Careers of Women in Medicine, Department of Medicine, Johns Hopkins University School of Medicine 2002-2004; Anaerobe Society of the Americas, President, 2010-2012; Clinical Infectious Diseases, Associate Editor, 2000-2016; U.S. Public Health Service/IDSA Guidelines for Prevention of AIDS-related Opportunistic Infections, Chair, Bacterial Enterics Group, 2010-present.

    Personal Statement: The greatest advances in health have come in infectious diseases.  Whether it is HIV, HCV, Helicobacter pylori or the microbiome, no field of medicine has been more transformative or exciting.  Despite the undeniable successes, for the foreseeable future, there remain important clinical, scientific, and public health challenges.  In addition, we must address critical gaps in recognition and reimbursement that especially threaten the next generation of infectious diseases practitioners.  Never before has the Society been more important to galvanize and coordinate our response to these challenges and those to come.

    During my 30 years as an infectious diseases physician, I have had the privilege of working in a broad range of activities that continue to renew my love for the field.  As a physician scientist, I have always seen patients and conducted research.  I also have had formal educational roles including being Director of the Infectious Diseases Fellowship Program at Johns Hopkins and being an Associate Editor for Clinical Infectious Diseases.  I have enjoyed long-standing service to the Society as a member of the Board of Directors and as the Society's treasurer.  It is in those roles that I gained a special appreciation for the Society's contributions to providing federal, state and community advocacy, improving services for our members, and educating the public about the value of infectious diseases specialists. If elected as Vice President, I will continue to advocate for better financial recognition for our critical clinical services and for more resources to conduct our critical missions in clinical care, research and public health.  I will seek to expand the Society's support for our young clinicians and investigators and work to engage and recruit the next generation.  I would be honored to have the opportunity to continue to work with our dynamic and engaged membership to address the exciting challenges ahead.

    IDSA Secretary Candidate - Sandra Abadie Kemmerly, MD, FIDSA, MACP

    Education: Louisiana State University, 1978; Louisiana State University School of Medicine, MD 1983; Alton Ochsner Medical Foundation, Intern and Resident and Resident in Internal Medicine, 1983-1986; Alton Ochsner Medical Foundation, Fellow in Infectious Diseases, 1986-1988.

    Current Appointment: Medical Director, Hospital Quality Ochsner Health System; ACGME Committee member.  Previous appointments  have included, but not limited to:  Medical Director, Infection Control; Medical Director, Clinical Practice Improvement; Medical Director, Employee Health; Medical Director, Clinical Practice Improvement; Medical Director, Advanced Practice Providers (CRNAs, NPs, PAs) of Ochsner Health System; Associate Chair, Department of Infectious Diseases, Ochsner Medical Center; Chairman, Performance Improvement Committee, Ochsner Medical Center;  President of the Medical Staff, Ochsner Clinic Foundation.

    IDSA Participation: IDSA Board of Directors, 2007-2010; Society Awards Committee, 2010-2013; Clinical Affairs Committee, 1999-2004; Annual Meeting Program Committee, 2001-2004; Louisiana/Mississippi Infections Diseases Society Board Member, 1997-present; Abstract reviewer for annual meeting, 2000-2007.

    Research and Areas of Clinical Interest: Epidemiology of emerging diseases, prevention of nosocomial and transplantation associated infections, and disaster preparedness.

    Other: Ochsner Clinic Foundation Hospital: Infection Control Committee Chair, 1996-2008; Therapeutics Committee, 1996-present; Critical Care Committee, 1996-2008; Staff Executive Committee, 2003-2015, Performance Improvement Committee, 1996-present; American Society for Microbiology; Society  for Healthcare Epidemiology of America; Association for Professionals in Infection Control & Epidemiology; American College of Physicians, Governor, State of Louisiana, 2003-2008; Chairman, Associate Committee, Louisiana Chapter, 1994-2003; Secretary, Governor's Council, Louisiana Chapter, 1995-1997; New Orleans Academy of Internal Medicine, President 2000-2001.

    Personal Statement: I feel I am uniquely qualified to serve on the IDSA Board of Directors because of my broad experience as an infectious disease clinician within the Ochsner Health System (OHS).  Ochsner Health System is one of the largest independent academic health systems in the United States and Louisiana's largest not-for-profit health system. With 28 hospitals owned, managed, and affiliated, more than 60 health centers, more than 17,000 employees, over 2,500 affiliated physicians in more than 90 medical specialties and subspecialties, Ochsner is Louisiana's largest health system. In addition, each year, more than 275 medical residents and fellows work in 27 different Ochsner-sponsored ACGME accredited residency training programs.

    I practice clinical infectious diseases in both ambulatory and hospital settings and oversee the infection control activities throughout Ochsner Health System. My clinical role includes attending on hospital rounds, and educating our fellows, residents, medical students during their ID rotations in the areas of infection control and antibiotic stewardship. In addition, I have experience in other medical societies, including serving as Governor of the Louisiana Chapter of the American College of Physicians for five years.

    I have been fortunate to serve IDSA in their governance and committee work.  Through committee activities and my work experiences, I have been able to develop an understanding of the role IDSA serves its membership and the community at large as they continue to improve the health of individuals, communities, and societies by promoting excellence in patient care, education, research, public health, and prevention as it relates to infectious diseases. 

    The Society's relentless focus on antimicrobial stewardship over the past decade is a testament to the accomplishments that can be made through advocacy, legislation, and public awareness efforts. Much has been accomplished, but far more needs to be achieved to combat the resistant bacterial challenges and overuse of antibiotics worldwide.  In addition, the Society has continued to play an active role as a thought leader in emerging and resistant organisms, epidemic preparation, and in global health issues such as Zika, Ebola, and HIV/AIDS.  As IDSA continues to provide leadership in all areas of infectious diseases, I would be honored to serve the Society and participate in these leadership activities to promote our specialty and better serve our communities. 

    IDSA Secretary - Larry K. Pickering, MD, FIDSA, FPIDS, FAAP

     Education:  West Virginia University School of Medicine, 1966-1970; Pediatric Intern and Resident, Pediatric Service, St. Louis Children’s Hospital, Washington University School of Medicine, St. Louis, MO., 1970-1972; Infectious Diseases Fellow, Washington University School of Medicine, 1972-1974.

    Current Appointments:  Senior Advisor to the Director, National Immunization Program/National Center for Immunization and Respiratory Diseases, Center for Disease Control and Prevention; 2001-2015;  Clinical Professor of Pediatrics, Emory University School of Medicine, 2001-2015; Adjunct Professor of Pediatrics, Emory University School of Medicine, 2016- current.

    IDSA Participation:  Board of Directors, 2001-2004; Scientific Program Committee, 2006-2009; Chair, Clinical Practice Guidelines for Immunization Programs for Infants, Children, Adolescents and Adults, 2009-2010; Awards Committee, 2010-2012;  21st Edward Kass Lectureship Award, 2011; Vice Chair, Scientific Program Committee, 2012-2013; Chair, Scientific Program Committee, ID Week, 2014; Guideline Panel, Clinical Practice Guidelines for Management of Infectious Diarrhea in Children and Adults; Co-chair, 2012-present.

    Research Interests:  Infectious Disease Enteric Study Center (NIAID), Protective factors in human milk (NICHD), Comprehensive Pediatric Treatment and Research Center for Children with AIDS (NIAID),Clinical Center for the Study of Pediatric Lung and Heart Complications of HIV (NHLBI),  Infections in Childcare Centers (CDC);Clinical and public health aspects of vaccines, 1977-2016.

    Other:   Edward J. van Liere Research Award, West Virginia University School of Medicine, 1970;  Outstanding clinical faculty member by the 1976 graduating senior class at the University of Texas Medical School (honorable mention in 1977 and 1981);  David R. Park Professor and Director of Pediatric Infectious Diseases at the University of Texas Medical School and MD Anderson Hospital, Houston, Texas, 1989-1992;  Committee for the Protection of Human Subjects, UT, Vice Chairperson, 1981-1982; Chairperson, 1983-1986;  Special Review Committee, NIH-NIAID, International Collaboration in Infectious Diseases Research, 1988;  Dean’s Teaching Excellence Award, University of Texas Medical School, 1985-1988;  Opportunistic Infection Committee, NIH-NIAID AIDS Clinical Trial Group, 1990;  president of the Pediatric Infectious Diseases Society (PIDS), 1995-1997;  Founder’s Award, Southern Society for Pediatric Research, 1994;  Distinguished Alumnus, West Virginia University School of Medicine, 1995; Pertussis Task Force, NIH-NIAID, 1996;  Award Selection Committee, American Society for Microbiology, 1999-2002; Program Committee, ICAAC, 1997-2002; NICHD Initial Review Group Study Section, 1998-2002;  Professor and Vice Chairman for Research and Director, Center for Pediatric Research, Eastern Virginia Medical School, 1996-2001; Chair, Research Committee , Section on Breastfeeding, American Academy of Pediatrics (AAP), 2001-2004;  Infectious Diseases Section Editor, National Health and Safety Performance Standards Guidelines for Out of Home Child Care Programs, 2002-2012;  member of the Board of Directors, program committee, and treasurer of the National Foundation for Infectious Diseases, 1997-2012; editor of five editions the AAP Red Book; 2000-2012; AAP liaison, Canadian Pediatric Society, Committee on Infectious Diseases, 1998-2003; co-editor of four editions of Principles and Practice of Pediatric Infectious Diseases; recipient of the 2007 Pediatric Infectious Disease Society’s Distinguished Physician Award; recipient of the national AAP 2010 Award for Lifetime Contributions :to Infectious Diseases Education; recipient of  a 2013 Outstanding Service Award from the Georgia chapter of the AAP;  recipient of the 2013 Distinguished Service Award from the Pediatric Infectious Diseases Society.   Recipient of the 2016 Stanley A. Plotkin Lectureship in Vaccinology Award from the Pediatric Infectious Disease Society;  executive secretary, Advisory Committee on Immunization Practices, CDC, 2005-2015; recipient of the 2016 John P. Utz Award in recognition of outstanding leadership skills from the National Foundation for Infectious Diseases.

    Personal Statement:  The Core Purpose of IDSA is to improve the health of individuals (people), communities and societies (http://www.idsociety.org/About_IDSA/ ). This core purpose is implemented by five core values: 1) enhancing the care of children and adults; 2) advocating sound and humane public policy; 3) promoting and sharing knowledge; 4) promoting collaboration, synergy, and cooperation; 5) advancing the discipline of infectious diseases.  These core values are diverse and challenging but must be met if IDSA is to continue to be the voice of infectious diseases.  One of the most important issues facing IDSA involves recruitment, education, and training of pediatric and adult infectious disease fellows.   If elected Secretary, I would be honored to work with other members of the Board of Directors and the outstanding IDSA staff. My experience as provided above in each of the core value areas has prepared me for this important position.

    Director #1 - Angela M. Caliendo, MD, PhD, FIDSA

    Education:  Case Western Reserve University School of Medicine, PhD, 1983; Case Western Reserve University School of Medicine, MD, 1987; Intern and Resident in Internal Medicine, Brigham and Women's Hospital, 1987-1990; Infectious Diseases Fellow, Massachusetts General Hospital and Harvard Medical School, 1990-1994.

    Current Appointments: Professor and Executive Vice Chair, Department of Medicine, Warren Alpert Medical School of Brown University; Director, Division of General Internal Medicine; Consulting Physician, Division of Infectious Diseases; Vice President, University Medicine Foundation.

    IDSA Participation:  Member of the Research Committee, 2011-2014; Chair of the Diagnostics Task Force, 2012-present, Enders Lecturer, 2011; Fellow IDSA, 2007; Editorial Advisory Board, Open Forum Infectious Diseases, 2015-present.

    Research Interests: Development of molecular diagnostic tests for the detection and quantification of infectious diseases and assessment of their clinical utility; standardization of transplant viral load testing; and evaluation of HIV-1 RNA burden in the genital tract of HIV-1 seropositive women. 

    Other: Vice Chair of Pathology and Laboratory Medicine, 2003-2013, Emory University School of Medicine; Director of Emory Medical Laboratories, 2001-2013; Director, Infectious Diseases, Emory University Hospital, 2007-2010;  ICAAC Program Committee, 2009-2013; President, Association of Molecular Pathology, 2004;  President, Pan-American Society for Clinical Virology, 2010-2012;  Chair, Microbiology Medical Devices Panel for the FDA, 2011-present; Member, Presidential Advisory Council on Combating Antibiotic Resistant Bacteria, 2015-present; Editor, Journal of Clinical Microbiology, 2013-present; Associate Editor, Journal of Clinical Virology, 2005- 2016; Editor, Clinical Microbiology Reviews, 2007-2012; Golden Apple Teaching Award and Anna Lee Boyett Award, Department of Pathology and Laboratory Medicine, Emory University SOM; Silver Pear Mentoring Award-Clinical, Department of Medicine, Emory University SOM; Ed Nowakowski Senior Memorial Clinical Virology Award, Pan American Society for Clinical Virology; BD Award for Research in Clinical Microbiology, American Society for Microbiology.

    Personal Statement: IDSA has long been influential in clinical practice, prevention, public health, education, research, and policy related to the practice of infectious diseases. Through my activities with IDSA, I have worked with exceptional staff and very dedicated colleagues that are committed to improving the health of individuals and communities and mentoring the next generation of ID physicians and scientists.  The changing healthcare landscape requires a focus on delivering cost-effective, high-quality care, while attracting trainees into the field. IDSA is very well positioned to significantly influence these activities.  My diverse professional experiences have focused on the integration of clinical practice and diagnostics, in particular establishing the clinical utility of molecular tests and educating clinicians on their proper use and interpretation.  As Chair of the Diagnostics Task Force, we have raised awareness of the central role of rapid diagnostics in practice of medicine and advocated for changes to the proposed FDA regulation of laboratory developed tests.  More recently, as a leader of a 200-physician practice plan, I have gained experience with insurance contracting, practice management and practice finances. I hope to serve and provide an important perspective to Society leadership in matters related to clinical practice, education and research.

    Director #1 - Luis Ostrosky-Zeichner, MD, FIDSA

    Education: Medical Doctor (Honors), Facultad de Medicina, Universidad Nacional Autonoma de México, México, 1989-1995; Internal Medicine Residency, Instituto Nacional de la Nutrición Salvador Zubirán/ Universidad Nacional Autonoma de México, México, 1995-1999; Infectious Diseases Fellowship, University of Texas- Houston Medical School and M.D. Anderson Cancer Center, Houston, Texas, USA, 1999-2002.

    Current Appointments:  Professor and Vice Chairman of Medicine for Quality, Division of Infectious Diseases, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas; Medical Director for Epidemiology, Memorial Hermann Texas Medical Center, Houston, Texas.

    IDSA Participation:       Standards and Practice Guidelines Committee (3 terms, last one as Chair); Guidelines translation bureau (2006-2012); Guidelines Task Force (2015-ongoing); Invasive Candidiasis Guideline Writing Group (2009 and 2016 guidelines); Candida work group, USPHS/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections (2007-ongoing); IDSA Clinical consultant, Centers for Disease Control and Prevention, 2012 fungal meningitis outbreak (October 2012); Invited Speaker to IDSA Annual meeting/IDWeek (2006, 2008, 2009, 2010, 2011, and 2014).

    Research Interests:  Medical mycology, Candida, healthcare epidemiology, antimicrobial stewardship, healthcare quality and performance improvement, emerging and re-emerging infections, hospital preparedness, neurocysticercosis, medical education, and information technology.

    Other:  Fellow of ACP and SHEA;  Senior Editor of JAC; Editorial board member of AAC, JCM, and Critical Care Medicine; SHEA/CDC Training Course in Hospital Epidemiology (2001); Texas Department of Health Judicious Use of Antibiotics Committee (2002); Texas Department of Health Advisor on Smallpox Vaccination (2003); NIH/NIAD Bacteriology and Mycology Study Group (2003-2007); Texas State Department of Health Services Advisory Panel on Healthcare-acquired infections (2005-2006); CLSI Committee on Antifungal Susceptibility Testing (2007-ongoing); Mycoses Study Group (2007-ongoing): Awards Committee, Society of Healthcare Epidemiology of America (2013-2015); SHEA representative to the CDC FAST teams for Ebola preparedness assessment for UTMB Galveston and Texas Children's Hospital (October 2014); Councilor, Medical Mycology Society of the Americas (2013-2016); Anti-Infective Drug Advisory Committee, Food and Drug Administration (2013-ongoing).

    Personal Statement:  Yes, I'm one of those doctors that always knew he wanted to do "ID."As an avid clinician, I live for the strange and interesting patient, for the new outbreak in a remote part of the world or in Wisconsin, for the new NHNS definitions, for looking into why that blood culture is taking too long, or to discuss the latest paper in journal club. I also live for keeping patients and staff safe, to make sense out of the information chaos with guidelines, and for trying that new antifungal in vivo for the first time. That's what I do every day, and it is that passion for our specialty that I want to share with more doctors-in-training, colleagues, and policy makers. I've worked in the guidelines enterprise of IDSA for more than 10 years in one capacity or another, and I see a position on the board as a way to consolidate all the important work we have done and to bring it to the next level of visibility and usefulness. Finally, as an internationally-trained physician, I have seen the key role that IDSA plays not only in our country, but in multiple regions, setting the tone and policy worldwide. I hope to bring an international perspective to the board and serve as a bridge between our society and other ID societies and groups. Thank you for your consideration.

    Director #2 - Daniel P. McQuillen, MD, FIDSA, FACP

    Education:  Georgetown University, BS, Biology, magna cum laude, 1981 (Alpha Sigma Nu, Phi Beta Kappa, Sigma Xi); The Medical College of Wisconsin, 1985; Intern and Resident in Internal Medicine, The Medical College of Wisconsin Affiliated Hospitals, 1985-1988; Infectious Diseases Fellow, The Maxwell Finland Laboratory for Infectious Diseases, Boston University School of Medicine, 1988-1991.

    Current Appointments:  Senior Physician, Center for Infectious Diseases and Prevention, Lahey Hospital & Medical Center, Burlington, MA; Assistant Professor of Medicine, Tufts University School of Medicine.

    IDSA Participation:  Member, Clinical Affairs Committee (CAC), 2004-2011, Chair, 2008-2011; Member, Quality Improvement Work Group, 2007-2011; Member, Value of ID Specialists Work Group, 2010-present; Chair, ID Valuation Work Group, 2012-present; IDSA Chair, IDWeek Program Committee, 2016, IDSA Vice Chair, 2015, Member, 2011-present; Faculty, IDSA Fellows' Meetings, 2005-2016; IDSA Alternate Advisor/Member-AMA/Specialty Society Relative Value Scale Update Committee (RUC), 2006-present; Co-Chair, IDSA Clinical Practice Meeting, 2009; Advocacy meetings with Congress supporting the Home Infusion Act of 2009 and legislation to reinstate payment for Consultation codes in 2011; with CMS staff and MedPAC Advisors about gainsharing, attribution, and system level value of ID specialists in 2009 and with MedPAC Advisors about incentivizing ID specialists in new payment delivery systems in 2011; co-author of two CAC-sponsored publications demonstrating the clinical and non-clinical value of ID specialists.

    Research Interests:  Value of clinical and non-clinical activities of ID specialists.

    Other:  President, Massachusetts Infectious Diseases Society (MIDS), 2013-present, Board of Directors, 2012-2013; elected Fellow, IDSA, 2009; elected Fellow, American College of Physicians, 2011; Kenneth Kaplan Clinician Award, MIDS, 2015; Castle Connolly Regional Top Doctors in Infectious Diseases, 2011-2016; Tufts University Excellence in Teaching Award, Medicine Third Year Clerkship, 2002-2004; NIH/NIAID Physician Scientist Award, 1991-1996; Maxwell Finland Young Investigator Award, MIDS, 1992; Diplomate, American Board of Internal Medicine in Internal Medicine and Infectious Diseases.

    Personal Statement:  The field of infectious diseases is constantly changing with new and reemerging challenges appearing almost daily.  IDSA has grown as an organization over my two-plus decades as a member to the point at which our Society is the preeminent national and international voice for infectious diseases.  At the same time that our healthcare environment has become increasingly complex, recognition and remuneration of our essential skills has not kept pace with the expanding demand for our expertise and the urgent need of the leadership our members provide.  ID specialists sit on the front lines of confronting healthcare-associated and emerging infections, countering the huge problem of antimicrobial resistance, and improving quality care of infections across all areas of medicine.  As our health care system evolves to more integrated care, we must rethink the positioning of our specialty, which cuts across all organ systems, acting at both the bedside and system-level, to also evolve in a manner that recognizes our value.   

    A decade of IDSA Clinical Fellows Meetings has confirmed for me that this recognition gap has played a major role in the recent decline in new trainees matching in our fellowship programs. There is no question in my mind that one of the greatest challenges facing our specialty today is fair reimbursement for our services.  My involvement on behalf of IDSA members in the AMA CPT-RUC process has given me a detailed understanding of the changes in medical economics facing ID clinicians today.  As Chair of the Clinical Affairs Committee (CAC) I helped begin the process of establishing a robust set of tools with supporting evidence that members can use to negotiate fair compensation for all our activities.  With CAC colleagues, I co-authored two papers published in Clinical Infectious Diseases that support the value of our non-clinical activities and clearly demonstrate the significant value of our clinical expertise.  As current Chair of the Valuation Work Group of the CAC, I lead our efforts to develop the concepts of ID Hospital Efficiency Improvement Programs that will house ID-led Antimicrobial Stewardship, Infection Prevention, OPAT, and Transitions of Care Programs with data to establish a more realistic Fair Market Value for our services.  Finally, as IDSA Chair of IDWeek 2016, my focus has been to deliver a meeting that is clearly relevant to all members of our societies regardless of clinical or academic focus.  Our specialty's inherently altruistic nature gives our expertise away with too much ease. We have to change that in order to secure our future. I would be excited and honored to continue advancing the goals of our Society as a member of the Board of Directors.

    Director #2 - J. Trees Ritter, DO, FIDSA

    Education:  Infectious Diseases Fellowship- University of California, Davis,  2004-2006; Residency- University of California, San Francisco / Alameda County Medical Center, 2001-2004; Medical Degree- Western University of Health Sciences, Pomona CA, 1997-2001; Undergraduate Degree- Cal Poly, San Luis Obispo, CA,  1991-1996.

    Current Appointments:  Founder and Managing Partner, Central Coast ID Consultants, 2006 - present; Chief Medical Officer, Marian Regional Medical Center, 2014 - present.

    IDSA Involvement:  IDSA Clinical Affairs Committee, Chair, 2013-2016; Member,  2009-2013; Value of the ID Specialist Task Force; Steering Group on ID Workforce; current;

    Quality Improvement Committee; Clinical Affairs Committee Liaison- current.

    Research Interests:  ID Physician value and compensation; ID practice regulation and health care reform; Murine CMV myocarditis.

    Personal Statement:   As Clinical Affairs Committee Chairman for 3 years and as a CAC member for 4 years prior to that, I have always kept our broad and diverse members' interests as my primary focus for advocacy.  As an IDSA director, I will continue to advocate for the entirety of our membership, especially our clinically focused members who are seeing unprecedented and increasingly demanding regulations thrust upon them.  Our ongoing advocacy will be vital to ensure the financial stability of our profession.

    An equally important task while CAC Chairman has been the goal of recruiting the best and the brightest to our wonderful profession.  Infectious diseases has seen a concerning decrease in visibility and interest, as manifested by an alarming decline in medicine residents choosing to do ID fellowships.  There is no single cause for this.  We must continue to focus our efforts on numerous different fronts to reverse this alarming trend.  This will involve educating medical students and residents (and the general public) about all we do as ID doctors.  We must now realize that the goals and motivations of many of our young physicians have evolved and are different than what they were in previous generations.  We have worked hard on the Clinical Affairs Committee to get this message out.  We have spearheaded IDSA's 'Value of the ID Physician' projects as well as publication of recent member surveys of compensation.  Together these have dispelled some of the myths of low compensation published by MedScape and others and have let people know that as an ID doctor you can have a very gratifying and financially fruitful career.

    As CAC chairman I have also been an advocate of strong ID-Led antimicrobial stewardship.  We must, as a society, develop and maintain our dominant position as the experts in stewardship and help our members leverage this to their benefit.

    As an IDSA director, I will continue to ensure that our profession moves into the future in this uncertain world with strength and ongoing, active engagement.  As decisions are made that directly affect us, we must continue to have a seat at the table.  

    HIVMA Representative to the IDSA Board of Directors Adaora A. Adimora, MD, MPH, FACP, FIDSA

    Medical Education:  Cornell University, BA, 1977; Yale School of Medicine, MD, 1981; Boston City Hospital, Boston, MA, Department of Medicine, Internship and Residency, 1981-1984; Montefiore/Albert Einstein College of Medicine, Department of Medicine, Clinical and Research Fellowship in Infectious Diseases, 1984-1986; University of North Carolina School of Public Health, Chapel Hill, NC, MPH, Epidemiology, 1993.

    Primary Current Professional Activity:  Professor of Medicine, University of North Carolina (UNC) School of Medicine; Professor of Epidemiology, UNC Gillings School of Global Public Health, UNC Chapel Hill.

    Other Relevant Professional Activities/Appointments: Fellow, IDSA; Fellow, American College of Physicians; HIVMA Board of Directors; Immediate Past Chair, HIVMA; Member, IAS Governing Council; Chair, Women at Risk Committee, HIV Prevention Trials Network; Member, US Department of Health and Human Services Antiretroviral Treatment Guidelines Panel; Principal Investigator, Women's Interagency HIV Study (WIHS) UNC Site; Editorial Board, Sexually Transmitted Diseases; Member, President's Council on HIV/AIDS; past member, National Institutes of Allergy and Infectious Diseases Advisory Council. 

    Position statement:  I have provided care for people living with HIV since I began my infectious diseases fellowship in 1984.  I have clinical, public health practice, and research experience.

    After my fellowship I was an infectious diseases attending at Harlem Hospital in New York.  After moving to North Carolina, I served as Assistant Chief for Science of the North Carolina state health department's Communicable Disease Control Section.  In this role, I helped develop and shape state public health policy and regulations related to control of HIV and other communicable diseases. 

    Since 1990 I have been a faculty member at UNC, where I treat patients in the clinic, inpatient ward, and consult services; and do research and teaching. My research examines social, behavioral, and biomedical factors that influence risk of acquiring HIV and experiencing adverse HIV-related outcomes.

    I have had the privilege of working with HIVMA for several years - first on the Board of Directors and most recently as Chair. In March of this year I testified on behalf of HIVMA to the US Senate's Committee on Aging about the recent hikes in drug prices. Despite recent victories in prevention and care, HIV providers and patients will continue to face major challenges in the near future:  not only the marked escalation of prices that place new and even off-patent medications out of reach, but also the gaps in compensation for HIV providers, assaults on research funding, need for expansion and diversification of the workforce, and increasing patients' access to care - especially in the substantial proportion of states that have not expanded Medicaid. 

    Our organization's leadership will be more critical than ever in successfully addressing these issues. I would be honored to serve providers and patients as HIVMA liaison to IDSA if elected.

    HIVMA Representative to the IDSA Board of Directors - Joel Gallant, MD, MPH, FIDSA

    Medical Education: University of California San Francisco, 1985 (MD); Yale-New Haven Hospital, 1989 (internal medicine residence and chief residency);  Johns Hopkins University School of Hygiene & Public Health, 1990 (MPH, international health);  Johns Hopkins Hospital, 1992 (infectious disease fellowship);Johns Hopkins University School of Medicine, Division of Infectious Diseases, 1992-2013 (faculty and Associate Director, Johns Hopkins AIDS Service).

    Primary Current Professional Activity: Medical Director of Specialty Services, Southwest CARE Center, Santa Fe, NM; Adjunct Professor of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine; Clinical Professor of Medicine,  Division of Infectious Diseases, University of New Mexico School of Medicine.

    Other Relevant Activities/Appointments: Fellow, Infectious Diseases Society of America and American College of Physicians; Former Chair, HIV Medicine Association; Board of Directors, International Antiviral Society-USA; Guidelines panel member, IAS-USA antiretroviral therapy guidelines panel and IDSA/HIVMA Panel for Primary Care Guidelines for the Management of Persons Infected with HIV; Infectious Disease Specialty Committee of the American Board of Internal Medicine; Recipient, 2006 HIV Clinical Educator Award from IDSA/HIVMA.

    Personal Statement: I have been caring for HIV-infected patients since the late 1980s and have been conducting clinical trials of HIV therapies since the early 1990s. Throughout my career, I have emphasized provider and patient education. In addition to writing research papers and review articles for practitioners, I also write frequently for the lay HIV press and maintain an interactive blog for lay readers. My book, 100 Questions and Answers about HIV and AIDS, is now in its third edition.  I served on the Board of Directors of HIVMA from 2008-2015, and was chair from 2013-2014. During that time I worked actively on many of HIVMA's advocacy priorities, including ensuring continued funding of the Ryan White HIV/AIDS Program, defining and maintaining the essential components of HIV care with transition to the Affordable Care Act, addressing HIV work force issues, defining HIV expertise, lobbying for focused practice recognition for HIV care at the American Board of Internal Medicine, passage of the HOPE Act, and fighting discriminatory anti-gay and anti-HIV legislation in sub-Saharan Africa.  My goal as HIVMA representative to the IDSA Board of Directors is to ensure that the HIVMA's advocacy and educational priorities are supported by IDSA and that the needs and concerns of HIV providers and their patients are represented on its board.

  • HIVMA Board of Directors 2016 Candidates

  • HIVMA Vice Chair - W. David Hardy, MD

    Medical Education:  University of Texas-Austin, BS, 1977; Baylor College of Medicine, MD , 1981; Internship, Baylor Affiliated Hospitals, Department of Medicine, 1981-1982; Residency, Harbor-UCLA Medical Center, Department of Medicine, 1982-1984; Fellowship, Infectious Diseases & Clinical Immunology, UCLA School of Medicine, Department of Medicine,  1984-1986; Post-MD Fellowship-Basic Retrovirology, Lab of Irvin Chen, PhD, David Geffen School of Medicine,  Department of Microbiology & Molecular Genetics, UCLA, 1998-2002;  Board Certified in Internal Medicine, 1984; Infectious Diseases, 2015.

    Primary Current Professional Activity: Senior Director of Evidence-based Practices (Research), Whitman-Walker Health, Washington, DC; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Clinical Professor of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC; Provide primary medical, HIV, HCV care for adolescent and adult patients at community-based, Federally Qualified Health Center (FQHC) in two locations in Washington, DC ; Oversee clinical research department conducting cohort studies; ACTG-sponsored clinical trials; CDC-sponsored PrEP in primary care implementation/adherence study; 32 Industry-sponsored trials.

    Other Relevant Activities/Appointments:  Board of Directors, HIVMA/IDSA, 2011-2014 (Research Award Committee, Capitol Hill Advocacy Day 2013,2014, CDC Working Group-Prevention 4 Positives Guidelines Committee, HOPE Act Implementation Work Group); HIVMA-sponsored: HIV criminalization defense testimony-2013-2015; Expert MD for Congressional Public Health Caucus-2016; Board of Directors, AAHIVM, 2006-2016 (Editor-in-Chief, Fundamentals of HIV Medicine for HIV Specialist textbook, 2008, 2009, 2012, 2016); NIH-sponsored research: ACTG Clinical Research Site (CRS) Leader-2015-2020 (Performance Evaluation Committee); Site PI, Multicenter AIDS Cohort Study (MACS)- 2015-2019 (Clinical Outcomes & Metabolic Working Groups); Site Co-PI, District of Columbia (DC) Cohort (Executive Committee), Member-District of Columbia Center for AIDS Research (DC CFAR); Co-Investigator, District of Columbia Martin Delaney HIV Cure Collaboratory (BELIEVE); Chief, Division of Infectious Diseases, Cedars-Sinai Medical Center; Associate Director, Cedars-Sinai-UCLA Multi-campus ID Fellowship Training Program, 2002-2013; Author of >125 research articles, book chapters, > 75 on-line CME-accredited publications.

    Personal Statement:  After 25 years of working in academic medicine at UCLA, I accepted a leadership position of the research department of a community-based FQHC in Washington, DC. I purposefully sought out Whitman-Walker Health due to its long-time reputation for serving all persons-in-need with a focus on the HIV-impacted and LGBT communities in a city with highest per capita HIV seroprevalence in the U.S.   Also in this position, I have the opportunity to better understand how HIV infection continues to heavily impact US communities of color, women, young and older MSM and transgender persons.  Once again, my eyes have been opened to the stark reality of health disparities in our country.

    While serving on the Board of HIVMA, I learned to appreciate the enormous value of our organization. I experienced its vital role in providing leadership, innovation, education and advocacy for HIV-focused medical professionals, our patients and our allies.  With the current, unpredictable national political climate, I believe that HIVMA's role in these areas is needed more than ever. Maintaining a strong and powerful voice in Washington, DC is a critical part of our mission. As Vice Chair, I endeavor to better leverage the resources, influence and collective voices of thousands of HIV care providers to:

    1. Advocate for continued federal funding for comprehensive and accessible medical care for our HIV+

    patients;

    1. Lobby for increased NIH funding to support ongoing and new basic and clinical investigations, especially

    development of an HIV cure and preventive vaccine;

    1. Continue to create professional HIV medical education programs to maintain a high level of evidence-

    based medical care for our patients;

    1. Fight the stigmatization and criminalization of persons living with HIV in the U.S.

     

    Please join me in this effort.

    HIVMA Vice Chair - Melanie Thompson, MD

    Medical Education: Emory University School of Medicine, MD, 1984; Emory University School of Medicine, Internal Medicine Residency, 1987. 

    Primary Current Professional Activity: Principal Investigator/Executive Director, AIDS Research Consortium of Atlanta (ARCA) Thacker, Thompson & Bernard MD clinical practice, Internal Medicine

    Other Relevant Professional Activities/Appointments:Current: Executive Editor, Strategy to End AIDS in Fulton County, Fulton County Task Force on HIV/AIDS; Chair, Prevention and Care Committee (2015-present); International Antiviral Society-USA Antiretroviral Guidelines Panel (Chair, 2009-2012; Member, 1995-2008, 2015-present); Department of Health and Human Services Antiretroviral Guidelines Panel (2015-present); Ryan White Medical Provider Coalition, National Steering Committee (2015-present); Ryan White Reauthorization Task Force, chair (2015-present); Georgia Department of Public Health: HIV Medical Advisory Committee (2014-present); Legal and Ethical Advisory Committee (2012-present); Metropolitan Atlanta HIV Health Services Planning Council; Public Policy Committee (2014-present); American Conference for the Treatment of HIV Planning Committee (2005-present).

    Past: HIV Medicine Association, Board of Directors (2012-2015); National Institutes of Health Office of AIDS Research Advisory Council Therapeutics Research Working Group (Chair, 2000-2002; Member, 1998-2016); Panel on Guidelines to Improve Entry Into and Retention In Care and Antiretroviral Adherence for Persons with HIV (Co-Chair, 2010-2012); Board of Directors, American Conference for the Treatment of HIV Foundation (2005-2013); Georgia Department of Public Health HIV Outreach, Testing, and Linkage to Care for African-American Men Who Have Sex with Men (MSM) (2011-2013); Georgia Department of Public Health Syphilis, Chlamydia, Gonorrhea Testing Project in MSM (2005-2011) ; Centers for Disease Control and Prevention (CDC) US Safety Study of Tenofovir as Chemoprophylaxis in HIV-Negative MSM (Principal Investigator 2003-2010) ; CDC Strategies for Testing African-American MSM (Principal Investigator 2006-2010); Acute Infection and Early Disease Network, University of Colorado Consortium (Principal Investigator 1999-2004; 2007-2009); HRSA Prevention with Positives Demonstration Project at DeKalb County Board of Health (Scientific Director, 2003-2008); CDC Prevention in Medical Care Settings Guidelines Evaluation Project (Principal Investigator 2003-2007); NIAID Community Programs for Clinical Research on AIDS (Principal Investigator 1989-2007); CDC Adult Spectrum of Disease Study (State of Georgia Principal Investigator, 1989-2004); NIH Office of AIDS Research, Panel to Define Principles of Therapy of HIV Infection (1997-1998); NIH Office of AIDS Research Advisory Committee (1993-1999); National Institute of Allergy and Infectious Disease (NIAID) AIDS Research Advisory Committee Founding Member (1989-1991); American Foundation for AIDS Research Community-Based Clinical Trials Network, (1989-1997; Chair Scientific Committee, 1996-1997)

    Personal Statement: In 1982, seeing my first AIDS patients, I was deeply moved by the challenge of providing care for people who had a complex and incurable disease, and who also were hated and feared for that disease as well as their sexual and/or gender identity. Fast-forward more than 30 years, and the clinical situation has changed dramatically. We have the tools to help people live rather than die with HIV and to prevent new infections. But here in the South, the hatred, fear and stigma have changed little for many people, especially the young black men at the heart of our epidemic. These factors compromise every step of our care continuum. In addition, our perfect storm includes an underfunded public health infrastructure, poverty, racism, poor health care access, and a dwindling clinical workforce. Therefore, I am increasingly involved in advocacy and policy work and now lead development of the Strategy to End AIDS in Fulton County. Likewise, serving on the HIVMA Board of Directors and the Ryan White Medical Provider Coalition Steering Committee has allowed me to contribute my front line perspective to federal policy discussions. I am eager to contribute to the leadership of HIVMA as Vice Chair, at a time when we desperately need increased advocacy to expand the ID and HIV workforce, protect and increase support for Ryan White funding and HIV research, and ensure that federal partners and lawmakers have a clear understanding of the social determinants that drive inequities at the core of America's HIV epidemic.   

    HIVMA Infectious Diseases Seat - Michelle Simone Cespedes, MD, MS

    Medical Education: Johns Hopkins University, Baltimore, MD, BS in Biophysics, 1994; Mount Sinai School of Medicine, New York, NY, MD, 1999; Internship and Residency in Internal Medicine, New York Presbyterian Hospital – Weill Cornell, New York, NY, 1999 – 2002; Fellowship in Infectious Disease, New York University School of Medicine, New York, NY, 2003 – 2005; Research Fellow in Infectious Disease, New York University School of Medicine, 2005 – 2006; New York University School of Medicine, MS in Clinical Investigation, 2012. Board Certified in Internal Medicine and Infectious Disease. 

    Primary Current Professional Activity: Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai (ISMMS); Physician Lead, Population Health HIV Disease Management Program, ISMMS; Co-Director, Clinical and Translational Research Center (CTRC) at Mount Sinai; Co-Director, ID Fellowship Research Curriculum, ISMMS; Chair, Underrepresented Populations Committee of the AIDS Clinical Trials Group(ACTG); Member, ACTG Executive Committee. 

    Other Relevant Activities/Appointments: Principal Investigator: Clinical Research Site Leader, Mount Sinai West Samuels Clinic; Vice Chair: ACTG 5240, Quadrivalent HPV Vaccine in HIV Infected Women; ACTG 5298, HPV Vaccine Efficacy in Anal Dysplasia in HIV Infected Populations; Investigator: Ryan White Title IV Women and Infants Service Grant Faculty/Educator: Biomedical Research Curriculum, Core Lecturer in Clinical Research and Biostatistics, Medical Education Program, Icahn School of Medicine at Mount Sinai; Teaching Attending, ISMMS Department of Medicine; Legacy Project Working Group member, NIH HIV/AIDS Network Coordination; section author “HIV in Women” for Up To Date; Board Member: Routes2Results, a non-profit public health research organization; Member of the following Organizations: American Medical Association; Infectious Disease Society of America; HIVMA, International AIDS Society – USA. 

    Personal Statement: I have been an active member of the HIV community for 20 years. I strive to ensure that populations disproportionately affected by HIV receive optimal care. Throughout medical school, I interned at a residential facility in the Bronx for people living with AIDS and substance abuse or mental health diagnoses. As a clinician, I soon became a community activist promoting HIV education, testing, and demystifying clinical trials. I continue to advocate PrEP uptake through community outreach to dispel misconceptions of HIV risk. I spent 10 years as the program director for HIV infected pregnant women and perinatally infected adolescents transitioning to adult care at Bellevue Hospital, a large public health hospital in NYC. There I had the unique opportunity to gain insight into HIV health care delivery in marginalized subpopulations including the homeless, incarcerated individuals, and undocumented immigrant communities. I developed my research career using the infrastructure of the AIDS Clinical Trials Group (ACTG). As Chair of the Underrepresented Population Committee for the ACTG, I continue to promote the early stage careers of minority junior investigators within the network as well as mentor minority students, house-staff, and junior faculty at Mount Sinai, located in East Harlem, NY. As a director of Sinai’s CTRC, I coordinate HIV research trials throughout the health system that provides access to over 10,000 HIV infected and nearly 5000 at risk, uninfected individuals. I believe I offer HIVMA a broad perspective on patient care delivery within the constraints of federal and state funding issues given my experience treating diverse populations.

    HIVMA Infectious Diseases Seat - Linda Gorgos, MD, MSc, FIDSA

    Medical Education: University of Rochester, Rochester, NY, BS Chemistry, BA Biology, summa cum laude, 1991; The Johns Hopkins University School of Medicine, Baltimore, MD, Doctor of Medicine, 1995; Residency, Internal Medicine, Department of Internal Medicine, The Massachusetts General Hospital, Boston, MA, 1995 - 1998; The London School of Hygiene and Tropical Medicine, University of London, London, UK, MSc with Distinction, Control of Infectious Disease, 2003 - 2004; The Gorgas Course in Clinical Tropical Medicine, Lima, Peru, Diploma in Tropical Medicine, 2005; Fellowship in Infectious Disease, Department of Allergy and Infectious Diseases, University of Washington, Seattle, WA, 2006 - 2009; Post-Doctoral Fellowship in STD Prevention, Association for Prevention Training and Research, Centers for Disease Control and Prevention, Atlanta, GA, 2008 - 2009; Board Certified in Internal Medicine (1998 - present) and Infectious Disease (2008-present).

    Primary Current Professional Activity: Infectious Disease Physician, Special Immunology Associates, El Rio Health Center, Tucson, AZ.

    Other relevant Activities/ Appointments: Fellow, Infectious Disease Society of America; Member, HIV Medicine Association; Core Faculty, International Antiviral Society - USA; Ryan White Medical Providers Coalition Steering Committee, 2013 - current; Consultant for the Sexually Transmitted Diseases Treatment Guidelines, Centers for Disease Control and Prevention, 2010- current; Invited Author, University of Washington Hepatitis Web Study, 2010-2011; Teaching Faculty, Seattle STD/ HIV Prevention Training Center, 2008 - 2009.

    Personal statement: My career encompasses a diversity of experience in HIV care, ranging from pubic heath and policy to clinical care. In my previous position I was responsible for the development of statewide planning, policy, and clinical oversight for the prevention and treatment of HIV, sexually transmitted infections, and viral hepatitis. This experience gave me insight into both the opportunities and barriers to incorporating these key services into the practical world of HIV care.  My clinical and educational work has focused on the care of sexually transmitted infections and integrating sexual health into HIV care. I serve as a consultant for the Centers for Disease Control and Prevention STD Treatment Guidelines with an emphasis on sexual health in minority populations.  Through my work with the Ryan White Medical Providers Coalition and HIVMA, I advocate with federal legislators and national policy makers to shape public policy, to address the needs of persons living with HIV, and to promote ongoing support for high quality HIV care. In my current position I provide specialty HIV care and primary care to a medically underserved population in a Ryan White funded clinic. This daily clinical work gives a me unique perspective on the evolving needs of patients, the many challenges faced by HIV medical providers, and the future obstacles to providing high quality HIV care and services in a changing medical landscape. I believe this breadth of experience and practical "on the ground" knowledge of the HIV care environment makes me well suited to serve on the HIVMA Board of Directors, and I hope to make a meaningful contribution to the future of HIV care.

    HIVMA Internal Medicine/Family Medicine Seat - Marwan Haddad MD, MPH, AAHIVS

    Medical Education: Harvard University, Cambridge, Massachusetts, Bachelor of Arts, 1991; McGill University School of Medicine, Montreal, Quebec, Canada, Doctor of Medicine, 1997; University of Toronto School of Medicine, Toronto, Ontario, Canada, Residency in Family Medicine, 1999;  Johns Hopkins School of Public Health, Baltimore, Maryland, Masters in Public Health, 2010. Board certified in Family Medicine, 2007; HIV medicine, 2007; Buprenorphine certified through DATA Waiver, 2006.

    Primary Current Professional Activity: Medical Director, Center for Key Populations, Community Health Center, Inc. (CHCI), Connecticut; Senior Researcher, Weitzman Institute, CHCI, Connecticut; Assistant Clinical Professor of Family Medicine, Frank H. Netter School of Medicine, Quinnipiac University, Connecticut.

    Other Relevant Activities/Appointments:Medical Director, Part C Early Intervention Services Grant, Ryan White HIV/AIDS Program, Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services, 2008 to present; Principal Investigator, Substance Abuse Service Expansion, HRSA, 2016 to present; Principal Investigator, Technology Enhanced Access to Coordinated Healthcare and Buprenorphine Maintenance Therapy (TEACH BMT) Project, Substance Abuse and Mental Health Services Projects of Regional and National Significance, Substance Abuse and Mental Health Services Administration (SAMHSA), 2013 to present; Clinical Director, CHC, Inc., Transforming Primary Care for Lesbian, Gay, Bisexual, Transgender (LGBT) People, Centers for Disease Control and Prevention (CDC)/National Association of Community Health Centers (NACHC)/Weitzman Institute/Fenway Institute ECHO-Based Project, 2016 to present; Originator and Lead Faculty, CHC Project ECHO  HIV/HCV and CHC Project ECHO Buprenorphine, medical provider training, guidance, and mentorship on HIV, HCV, and Buprenorphine management through weekly didactic and case-based teaching, 2012 to present; Clinical Mentor, Capstone Project, Frank H. Netter MD School of Medicine, Quinnipiac University, 2015 to present; Specialty Faculty, Nurse Practitioner Residency in Family Practice and Community Health, CHC, Inc., 2007 to present; Research Preceptor, Health of Communities Course, Wesleyan University, Middletown, Connecticut, 2008 to present; Chair, HIV Quality Improvement Committee, CHC, Inc., 2008 to present; Member, Committee of Medical Directors, CHC, Inc., 2008 to present; Member, Medical Quality Improvement Committee, CHC, Inc., 2006 to present; Member, Infection Control Committee, CHC, Inc., 2012 to present; Member, National Viral Hepatitis Roundtable, 2012 to present; Lead Consultant, NACHC Hepatitis C Fact Sheet, Buprenorphine Fact Sheet, 2015; Member, Hepatitis C Work Group, American Association for the Study of Liver Diseases/American Gastroenterological Association Institute/The American Medical Association-convened Physician Consortium for Performance Improvement®, 2012-2013;  Recipient, Primary Care Leadership Award, for integrating HIV, HCV, and substance use management in primary care, Connecticut Center for Primary Care, 2011; Cumulative GPA 4.0, Johns Hopkins School of Public Health; Chief Resident, Wellesley/St. Michael's Hospital, Family Medicine Program, University of Toronto School of Medicine; Chair, Section of Residents, College of Family Physicians of Canada; Dean's Honor List, McGill University School of Medicine; Cum Laude, General Studies, Harvard University; Dean's Honor List, Harvard University.

    Personal Statement: From the beginning of my career, my focus has been the integration of HIV medicine in primary care. In the past 10 years, I have led the growth of CHCI's Ryan White-funded HIV program from a specialty-based to a primary care model, spearheading its incorporation into the patient centered medical home. As Medical Director of the Center for Key Populations, I ensure access to and delivery of evidence-based quality care for 5 key groups with the highest burden of and risk for HIV: men who have sex with men, transgender people, people who inject drugs, the recently incarcerated, and sex workers. I recognize the intersecting nature of HIV, HCV, and substance abuse and the importance of screening, prevention, and management of these diseases in primary care. I have been a champion of the underserved and disenfranchised populations at the local and state level, advocating for better care and access to services.

    I established and lead CHC's Project ECHO HIV, HCV, and Buprenorphine, offering ongoing learning, support, and consultation through video conferencing with medical providers from clinics in Connecticut and across the U.S. I also teach and lecture at state and national conferences on HIV, integrated care, and various other topics.

    I am excited and enthusiastic to serve on the HIVMA Board. I feel my commitment to serving individuals who are infected and affected by HIV in primary care combined with my drive to transform clinical care through innovation and research make me an ideal candidate for this position.

    HIVMA Internal Medicine/Family Medicine Seat - James M. Sosman, MD, FACP

    Medical Education: M.D., University of Chicago, Pritzker School of Medicine, Chicago, IL (1985): Internship, Residency, and Chief Residency, Internal Medicine, Stanford University Medical Center, Stanford, CA (1985-1989):Graduate Studies in Clinical Epidemiology and Health Policy, Department of Preventive Medicine, University of Wisconsin Graduate School, Madison, WI (1995-1999);Medical Education Development and Leadership Teaching Program, University of Wisconsin Medical School, Madison, WI (1998-1999): Primary Care Faculty Development Fellowship, University of Wisconsin School of Medicine and Public Health, Madison, WI (2006-2007)

    Primary Current Professional Activity: Professor of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI; Medical Director, HIV/AIDS Comprehensive Care Program, University of Wisconsin Hospital and Clinics, Madison, WI; Chair, General Internal Medicine Research Section & Fellowship Director, General Internal Medicine University of Wisconsin School of Medicine and Public Health, Madison, WI                    

    Other Relevant Activities/Appointments: Director of Medical Education and Principal Investigator, Midwest AIDS Training and Education Center of Wisconsin (AETC) (1998-present);Society of General Internal Medicine, Former Chair, AIDS Task Force and HIV Interest Group; National Board Member, American Academy of HIV Medicine; Director, Wisconsin's HIV Treater's Meeting, Wisconsin State-wide monthly clinical case conference: Selection Committee:  Lawrence Linn Award for research to improve quality of life for people living with HIV, Society of General Internal Medicine (SGIM);Consultant: CDC National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP): Guidance for Routine HIV Testing in Correctional Settings; Consultant:  CDC National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP): Guidance for Routine HIV Testing in Primary Care Settings; Consultant:  CDC National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP): Guidance for STD and HIV Partner Services; Ad hoc Reviewer:  NIH NHLBI Study Section:  Mechanisms and Management of Cardiovascular and Metabolic Complications of HIV/AIDS (2008);Co-Investigator/UW Site Principal Investigator.  "Seek, Test and Treat:  Addressing HIV in the Criminal Justice System in Wisconsin."  NIMH/NIAID (2011-2016);Co-Investigator/UW Site Principal Investigator.  "Special Projects of National Significance:   Systems Linkages and Access to Care for Populations at High Risk of HIV Infection Initiative."  HRSA (2011-2016);Principal Investigator.  "UWHC Ryan White EIS Program Part B." Wisconsin Department of Health Services.  (2012-2017);Principal Investigator.  "UWHC Ryan White EIS Program Part C."  HRSA (2015-2018);Principal Investigator "AIDS Education and Training." Wisconsin Department of Health Services.  (2008-2017)

    Personal Statement: I am a practicing general internist, HIV specialist, and academician. I maintain a full array of academic and clinical roles involving medical education, health policy, research and programmatic leadership. All of these efforts have underscored my desire to promote the highest quality of care for the most vulnerable in our society, which has included those infected and affected by HIV. I serve as Medical Director, HIV Care Program, University of Wisconsin School of Medicine and Public Health, and principal investigator on HRSA Ryan White Part B, C, and SPNS grants to support this program. I am also Medical Director of the Midwest AIDS Training and Education Center of Wisconsin (MATEC-WI), a HRSA supported AETC. My academic focus includes HIV and STI prevention for at risk men, HIV medication adherence, cardiovascular complications of HIV, and healthcare and risk reduction for men with a history of incarceration. On the national level, I am a Board Member of the American Academy of HIV Medicine (AAHIVM), and I am the former Head of the Society of General Internal Medicine's (SGIM) HIV/AIDS Task Force. I have also participated as a consultant to the CDC and HRSA regarding HIV screening, partner services and efforts to maintain the HIV clinical workforce. In these roles, I advocate for ability to provide the best HIV care to our communities and encourage future clinicians towards excellence in HIV care.  I look forward to the opportunity to serve on the HIVMA Board to promote these efforts within this influential organization.

    HIVMA Internal Medicine/Family Medicine Seat - Ira B. Wilson, MD, MSc, FACP

    Medical Education: Harvard College, AB, 1979; Harvard Medical School, MD, 1987; Chan School of Public Health (Harvard), MSc, 1993; Internship and Residence, Beth Israel Hospital, Boston MA, 1987-1990; Chief Resident, Medicine, Beth Israel Hospital, Boston MA, 1992-1992; Fellowship in General Medicine, Harvard and Beth Israel Hospital, Boston, MA, 1991-1993

    Primary Current Professional Activity: Professor and Department Chair, Health Services, Policy & Practice, Brown University School of Public Health; Professor of Medicine, Alpert Medical School, Brown University; Primary care physician, Providence VA Medical Center.

    Other Relevant Activities/Appointments: Chair, Society of General Internal Medicine, Research Committee (2006-2009); Chair, Society of General Internal Medicine, Health Policy Committee, Research Subcommittee (2009-2012); Co-Chair of the Working Group "Reinventing Medicaid"(Appointed by Governor Raimondo), 2015; Member, RI Working Group for Heath Care Innovation (Appointed by Governor Raimondo), 2015-2016; National Co-Chair, Behavioral Science Advisory Group to HANC (HIV/AIDS Network Coordination), 2013-present; Member, National Advisory Panel to IMPAACT Network (International Maternal Pediatric Adolescent AIDS Clinical Trials), 2014; Member, Advisory Committee on Social Science and Health Systems Research, International AIDS Society CURE Initiative, 2014-2016; Member, External Advisory Group to Behavioral Science Working Group, NIH Division of AIDS, Microbicide Treatment Network, 2015; Chairperson, NIAID Special Emphasis Panel ZAI1 UKS-A(S1), Innovative Measures of Oral Medication Adherence for HIV Treatment and Prevention (R01), July 2015; Co-Director, Outcomes and Biostatistics Core, Lifespan/Tufts/Brown Center for AIDS Research (CFAR), 1998-2010; Co-Director, Developmental Core, Lifespan/Tufts/Brown CFAR, 2010-present.

    Personal Statement: I was a first year medical student in 1983 when the HIV virus was identified, and improving the care of persons with HIV has been a major theme of my professional life ever since those early and difficult years of the epidemic. As medical student, resident, and fellow I cared for patients with multiple complications of HIV before the development of effective ART. As a junior faculty member my research focused in measuring and improving the quality of HIV care, and in particular issues related to adherence with ART. I have been continuously funded by the NIH to do HIV-related work since 1998, and from 2004 to 2016 I had a K24 (mid-career mentoring award) from NIMH which allowed me to be a research mentor for junior faculty throughout the US. I have also held a number of research-related leadership positions in the Society of General Internal Medicine that involve lobbying Congress for improved funding for research. Were I fortunate enough to have the privilege to serve on the Board of the HIV Medical Association, I would bring to this position my ongoing interest in and commitment to career mentoring, HIV research, and health policy.

    HIVMA Non-Designated Seat - Lori A. Gordon, PharmD, BCPS, AAHIVP

    Medical Education: Florida A & M University, Tallahassee, FL, 2010 (PharmD, Summa Cum Laude); Michael E DeBakey VA Medical Center, Houston TX, 2010 - 2011 (PGY-1 Pharmacy Practice Residency); James J Peters VA Medical Center, Bronx, NY, 2011 - 2012 (PGY-2 Infectious Diseases Practice Residency); National Institutes of Health, Bethesda, MD, 2012 - 2014 (HIV Clinical Pharmacokinetics Fellowship); Board Certified Pharmacotherapy Specialist (BCPS), 2012; HIV Pharmacist (AAHIVP), 2012.

    Primary Current Professional Activity: Clinical Assistant Professor, Xavier University of Louisiana (XULA), College of Pharmacy; Clinical Pharmacy Specialist- HIV/Hepatitis C, University Medical Center New Orleans (UMCNO) Infectious Diseases Center; Clinical Assistant Professor of Medicine (gratis), Louisiana State University Health Sciences Center, School of Medicine, New Orleans, LA.

    Other Relevant Activities/Appointments:Principal/Lead Investigator- Acceptance of a Community pharmacy Collaborative to Ensure Solutions for Seekers of Pre-Exposure Prophylaxis (supported by Society of Infectious Diseases Pharmacists [SIDP] Infectious Diseases Pharmacotherapy Young Investigator Research Award), Influence of cobicistat or ritonavir on dabigatran pharmacokinetics and pharmacodynamics in health volunteers (supported by National Institutes of Health Intramural Program); Co-Investigator- Assessment of the Barriers to and Benefits of AAHIVP credentialing (American Academy of HIV Medicine [AAHIVM]); Clinical Pharmacy Research Services- GS-US-380-1489, GS-US-380-1490, GS-US-380-1844, GS-US-380-1878, GS-US-311-1717 (Gilead Sciences); Trustee- NO/AIDS Task Force dba CrescentCare; Member- HIV Medicine Association, Infectious Diseases Society of America, American Academy of HIV Medicine [member & Pharmacists Committee], Society of Infectious Diseases Pharmacists, Quality Committee (NO/AIDS Task Force dba CrescentCare), Continuous Quality Improvement Committee (UMCNO ID Center), American College of Clinical Pharmacy, American Society of Health-system Pharmacists, South-Eastern Louisiana Society of Health-system Pharmacists [President-Elect]; Preceptor/Advisor- PrEP Medical Consultant (Louisiana Office of Public Health, STD/HIV Program), PGY-1 Pharmacy Practice Residency [clinical & research] (XULA), Inter-Professional Student Alliance PrEP Advisor (XULA).

    Personal Statement: Eight years ago, I was introduced to a therapeutic area of interest [HIV] with overwhelming public health implications. In my current position, I provide HIV clinical pharmacy services concentrated within the infectious diseases fellows' clinics, as well as, medication counseling to patients on antiretrovirals, (hepatitis C) direct acting antivirals, and medications for cardio-metabolic co-morbidities. I also precept pharmacy students & residents throughout most of the year, and serve as the lead research mentor on pharmacy residency projects annually. My research interests approach the pharmacist's role in ensuring health equity via two different pathways. My pharmacokinetic research serves to address paucities in knowledge regarding drug-drug interactions between antiretrovirals and other medications used to treat patients' chronic co-morbidities. My implementation research focuses on reducing health disparities, especially in underserved populations, by examining the actualization of biomedical interventions [such as PrEP for HIV prevention in HIV-negative individuals and statins for primary prevention in HIV-positive individuals] in high-risk yet low-uptake communities. I was recently invited to join the Board of Trustees for NO/AIDS Task Force dba Crescent Care, the oldest and one of the largest HIV/AIDS service organizations in New Orleans. I also serve and remain active within local, regional, national pharmacy organizations, including the Southeast Louisiana Society of Health-system Pharmacists and the American College of Clinical Pharmacy. It would be an honor and privilege to serve on the HIVMA Board, representing the perspective of a pharmacy clinician, educator, and scientist, and working to further promote fair policy and quality care for our patients.

    HIVMA Non-Designated Seat - James Lester Harmon, DNP, RN, ANP-BC, AAHIVS

    Education: University of San Francisco, Bachelor of Science in Nursing, 1992; Duke University School of Nursing, Master of Science in Nursing, 1997, and Doctor of Nursing Practice, 2012.

    Primary Current Professional Activity: Associate Professor and Director of the HIV Specialty for Nurse Practitioners at the Duke University School of Nursing; Nurse Practitioner at Warren-Vance Community Health Center, Henderson, NC (Ryan White Part C Clinic).

    Other Relevant Activities/Appointments: Lead Faculty for the Adult Gerontology Nurse Practitioner Primary Care Program, Duke University School of Nursing (DUSON); Principal Investigator and Project Director for a National AIDS Education and Training Center/HRSA 5-year grant (2013-18); Teach courses in HIV pathogenesis, epidemiology, and clinical management, responsible for integrating HIV content into the general curriculum for all of our nurse practitioner students; Memberships in HIVMA, IDSA, Association of Nurses in AIDS Care (ANAC), and the American Academy of HIV Medicine; 2014 article of the year (Richard L. Sowell Article Award, Journal of the Association of Nurses in AIDS Care (JANAC);  Guest Co-Editor for a special issue of JANAC devoted to US and global HIV workforce development (May-June, 2016);  Provided primary care to people with HIV infection and coordinated HIV clinical research studies in the Division of Infectious Disease, Duke University Medical Center (1997-2007); Worked on a research team at DUSON examining HIV-related fatigue in a 3-year longitudinal study (2007-2010); Published in 14 peer-reviewed publications; Provide primary care to a rural HIV-infected population at the Warren-Vance Community Health Center/Northern Outreach Clinic in Henderson, NC (1997-present); Specialty certification in HIV medicine, American Academy of HIV Medicine (2008-present).

    Personal Statement: I began my career in nursing in San Francisco in 1992, and I have devoted my entire career to improving the lives of people with HIV infection. When I became a Nurse Practitioner at Duke in 1997, combination antiretroviral therapy was just beginning to reduce the death rates from AIDS, and it was a very exciting time to enter practice. Through my affiliation with Duke, I have had the privilege to work with and learn from many experts in the field of HIV nursing and medicine. Engaging in a combination of clinical practice, clinical research, and teaching has been an incredibly rich and rewarding experience. At this time in my career, I am very excited to be contributing to the development of a new generation of HIV care providers by educating nurse practitioners in the HIV specialty at the Duke School of Nursing. I am also very grateful that I have the opportunity, through my clinical practice, to contribute to the health and well-being of people living with HIV infection in the rural South. I am very honored to be nominated for a Board seat for HIVMA, and I feel my extensive experience in HIV clinical practice, research, and education will enable me to make a meaningful contribution to the work of the Board if elected.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site